EF Hutton Maintains Merus N.V. (MRUS) Buy Recommendation
Fintel reports that on April 14, 2023, EF Hutton maintained coverage of Merus N.V. (NASDAQ:MRUS) with a Buy recommendation.
Analyst Price Forecast Suggests 76.80% Upside
As of April 7, 2023, the average one-year price target for Merus N.V. is $38.45. The forecasts range from a low of $33.33 to a high of $49.35. The average price target represents an increase of 76.80% from its latest reported closing price of $21.75.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Merus N.V. is $41MM, a decrease of 0.83%. The projected annual non-GAAP EPS is -$3.45.
What are Other Shareholders Doing?
NORTHERN FUNDS - NORTHERN SMALL CAP CORE FUND Class K holds 13K shares representing 0.03% ownership of the company. In it's prior filing, the firm reported owning 13K shares, representing an increase of 1.94%. The firm decreased its portfolio allocation in MRUS by 27.98% over the last quarter.
FBIOX - Biotechnology Portfolio holds 459K shares representing 0.99% ownership of the company. In it's prior filing, the firm reported owning 630K shares, representing a decrease of 37.45%. The firm decreased its portfolio allocation in MRUS by 53.97% over the last quarter.
Norges Bank holds 75K shares representing 0.16% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
NUSC - Nuveen ESG Small-Cap ETF holds 35K shares representing 0.07% ownership of the company. In it's prior filing, the firm reported owning 31K shares, representing an increase of 10.37%. The firm decreased its portfolio allocation in MRUS by 24.39% over the last quarter.
RBB FUND, INC. - Adara Smaller Companies Fund holds 47K shares representing 0.10% ownership of the company. No change in the last quarter.
What is the Fund Sentiment?
There are 153 funds or institutions reporting positions in Merus N.V..
This is an increase
of
5
owner(s) or 3.38% in the last quarter.
Average portfolio weight of all funds dedicated to MRUS is 0.40%,
a decrease
of 32.92%.
Total shares owned by institutions increased
in the last three months by 8.86% to 39,389K shares.
The put/call ratio of MRUS is 0.08, indicating a
bullish
outlook.
Merus N.V Background Information
(This description is provided by the company.)
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
See all Merus N.V. regulatory filings.This story originally appeared on Fintel.